Previous close | 16.85 |
Open | 16.93 |
Bid | 16.75 x 100 |
Ask | 16.90 x 200 |
Day's range | 16.69 - 17.05 |
52-week range | 10.68 - 20.73 |
Volume | |
Avg. volume | 121,824 |
Market cap | 2.868B |
Beta (5Y monthly) | 0.66 |
PE ratio (TTM) | 28.00 |
EPS (TTM) | 0.60 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 28.47 |
HUTCHMED (China) (LON:HCM) has had a great run on the share market with its stock up by a significant 7.1% over the...
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If approved, would confirm 2021 conditional approval and expand indication to more patients — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application (“sNDA”) for
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the registration stage of the Phase II/III clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China. This follows positive data from the proof-of-concept Phase II stage of the trial and subsequent consultation with the China National Medical Products A